Cohort of Liver Transplanted Patients With Hepatitis C Virus Recurrence and Treated With Direct-acting Antiviral Agents
Phase of Trial: Phase IV
Latest Information Update: 05 Aug 2019
Price : $35 *
At a glance
- Drugs Daclatasvir/sofosbuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Peginterferon (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary) ; Antivirals
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ANRSCO23CUPILT
- 05 Aug 2019 Results (n=67) assessing the changes to blood concentrations of Cyclosporine or Tacrolimus and to rule out any drug-drug interactions during SOF/DCV-based antiviral therapy in liver transplant recipients published in the European Journal of Clinical Pharmacology
- 27 Apr 2018 Status changed from active, no longer recruiting to completed.
- 17 Apr 2018 Results (n=139) assessing safety of sofosbuvir regimens after liver transplantation longitudinal assessment of renal function, were published in the Alimentary Pharmacology and Therapeutics.